Clinical Infectious Diseases: Open Access

ISSN: 2684-4559

Open Access

Citations Report

Clinical Infectious Diseases: Open Access : Citations & Metrics Report

Articles published in Clinical Infectious Diseases: Open Access have been cited by esteemed scholars and scientists all around the world.

Clinical Infectious Diseases: Open Access has got h-index 3, which means every article in Clinical Infectious Diseases: Open Access has got 3 average citations.

Following are the list of articles that have cited the articles published in Clinical Infectious Diseases: Open Access.

  2021 2020 2019

Year wise published articles

29 23 5

Year wise citations received

4 4 1
Journal total citations count 49
Journal 5 years impact factor 0.14
Journal cite score 0.14
Journal h-index 3
Journal h-index since 2018 2
Important citations

Péchiné, Séverine, Claire Janoir, and Anne Collignon. "Emerging monoclonal antibodies against Clostridium difficile infection." Expert opinion on biological therapy 17, no. 4 (2017): 415-427.

Prabhu, Vimalanand S., Oliver A. Cornely, Yoav Golan, Erik R. Dubberke, Sebastian M. Heimann, Mary E. Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, and Stephen Marcella. "Thirty-day readmissions in hospitalized patients who received bezlotoxumab with antibacterial drug treatment for Clostridium difficile infection." Clinical Infectious Diseases 65, no. 7 (2017): 1218-1221.

Negm, Ola H., B. MacKenzie, M. R. Hamed, O. A. J. Ahmad, Clifford C. Shone, D. P. Humphreys, K. Ravi Acharya et al. "Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration." Clinical & Experimental Immunology 188, no. 3 (2017): 437-443.

Chapin, Ryan W., Tiffany Lee, Christopher McCoy, Carolyn D. Alonso, and Monica V. Mahoney. "Bezlotoxumab: could this be the answer for Clostridium difficile recurrence?." Annals of Pharmacotherapy 51, no. 9 (2017): 804-810.

Rees, William D., and Theodore S. Steiner. "Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy." European journal of immunology 48, no. 3 (2018): 398-406.

Kufel, Wesley D., Aaron S. Devanathan, Ashley H. Marx, David J. Weber, and Lindsay M. Daniels. "Bezlotoxumab: a novel agent for the prevention of recurrent Clostridium difficile infection." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37, no. 10 (2017): 1298-1308.

Goldstein, E. J. C., S. J. Johnson, P-J. Maziade, C. T. Evans, J. C. Sniffen, M. Millette, and L. V. McFarland. "Probiotics and prevention of Clostridium difficile infection." Anaerobe 45 (2017): 114-119.

Navalkele, Bhagyashri D., and Teena Chopra. "Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection." Biologics: targets & therapy 12 (2018): 11.

Song, Jung Hoon, and You Sun Kim. "Recurrent Clostridium difficile infection: risk factors, treatment, and prevention." Gut and liver 13, no. 1 (2019): 16.

Varshney, Avanish K., Galina A. Kuzmicheva, Jian Lin, Kevin M. Sunley, Rodney A. Bowling Jr, Tzu-Yu Kwan, Heather R. Mays et al. "A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia." PLoS One 13, no. 1 (2018): e0190537.

Kelly, Brendan J., and Pablo Tebas. "Clinical practice and infrastructure review of fecal microbiota transplantation for Clostridium difficile infection." Chest 153, no. 1 (2018): 266-277.

Hui, Wenjia, Ting Li, Weidong Liu, Chunyan Zhou, and Feng Gao. "Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis." PloS one 14, no. 1 (2019): e0210016.

Gupta, Swati B., Vinay Mehta, Erik R. Dubberke, Xuemei Zhao, Mary Beth Dorr, Dalya Guris, Deborah Molrine et al. "Antibodies to toxin B are protective against Clostridium difficile infection recurrence." Clinical Infectious Diseases 63, no. 6 (2016): 730-734.

Relevant Topics

arrow_upward arrow_upward